期刊文献+

Differential expression and function of the endogenous lactate receptor, GPR81, in ERα-positive/HER2-positive epithelial vs. post-EMT triple-negative mesenchymal breast cancer cells

原文传递
导出
摘要 Aim:Lactate can signal through the endogenous lactate receptor,GPR81,which is expressed in some cancers.Lactate metabolism is altered by the metastasis-promoting process of epithelial-mesenchymal transition(EMT).This study examined the expression and function of GPR81 in breast cancer samples,and in receptor-positive epithelial vs.triple-negative post-EMT mesenchymal breast cancer cells.Methods:GPR81 mRNA expression was examined by breast cancer microarray,and by a Kaplan-Meier survival curve.Using 3-dimensional culture conditions,GPR81 mRNA expression in epithelial and mesenchymal breast cancer cell lines was measured by qRT-PCR.GPR81 siRNA was used to assess the role of GPR81,alone or in conjunction with tamoxifen,in the regulation of MCT1 and MCT4 lactate transporters,intracellular lactate,and cell proliferation and survival.Results:GPR81 mRNA levels were elevated in receptor-positive breast cancer,relative to non-tumor and triple-negative samples,and correlated with increased survival.GPR81 expression was elevated in the two epithelial breast cancer cell lines vs.the corresponding post-EMT mesenchymal cell lines.GPR81 knock-down in epithelial MCF7 cells caused:1,selectively lower mRNA and protein expression of the MCT1 transporter,but not MCT2 or MCT4 ;transporters;2,lower levels of intracellular lactate;and 3,decreased proliferation and survival in lactate only-containing conditions.GPR81 siRNA plus tamoxifen displayed additive suppressive effects on MCT1 expression and cell viability.Conclusion:GPR81 promotes the ability of epithelial breast cancer cells to import lactate for energy use.As such,GPR81 represents a potential target for treatment of hormone-positive breast cancer cells,and may be prognostic for higher grade breast cancer.
出处 《Journal of Cancer Metastasis and Treatment》 2019年第6期1-14,共14页 癌症转移与治疗(英文版)
基金 the Fund for Biology from the Cell Biology Department at the University of Connecticut Health Center
  • 相关文献

参考文献1

  • 1Michele Orditura,Gennaro Galizia,Vincenzo Sforza,Valentina Gambardella,Alessio Fabozzi,Maria Maddalena Laterza,Francesca Andreozzi,Jole Ventriglia,Beatrice Savastano,Andrea Mabilia,Eva Lieto,Fortunato Ciardiello,Ferdinando De Vita.Treatment of gastric cancer[J].World Journal of Gastroenterology,2014,20(7):1635-1649. 被引量:121

二级参考文献11

  • 1Muhammed Ashraf Memon,Nick Butler,Breda Memon.The issue of lymphadenectomy during laparoscopic gastrectomy for gastric carcinoma[J].World Journal of Gastrointestinal Oncology,2010,2(2):65-67. 被引量:10
  • 2Wei-guo Zhu,Da-fu Xua,Jun Pu,Cheng-dong Zong,Tao Li,Guang-zhou Tao,Fu-zhi Ji,Xi-lei Zhou,Ji-hua Han,Cheng-shi Wang,Chang-hua Yu,Jiang-guo Yi,Xi-long Su,Jin-xia Ding.A randomized, controlled, multicenter study comparing intensity-modulated radiotherapy plus concurrent chemotherapy with chemotherapy alone in gastric cancer patients with D2 resection[J]. Radiotherapy and Oncology . 2012 (3)
  • 3Mun Ki Choi,Gwang Ha Kim,Do Youn Park,Geun Am Song,Dong Uk Kim,Dong Yup Ryu,Bong Eun Lee,Jae Hoon Cheong,Mong Cho.Long-term outcomes of endoscopic submucosal dissection for early gastric cancer: a single-center experience[J]. Surgical Endoscopy . 2013 (11)
  • 4Andrea Coratti,Mario Annecchiarico,Michele Di Marino,Edoardo Gentile,Francesco Coratti,Pier Cristoforo Giulianotti.Robot-assisted Gastrectomy for Gastric Cancer: Current Status and Technical Considerations[J].World Journal of Surgery.2013(12)
  • 5Benjamin Schmidt,Nicole Look-Hong,Ugwuji N. Maduekwe,Kevin Chang,Theodore S. Hong,Eunice L. Kwak,Gregory Y. Lauwers,David W. Rattner,John T. Mullen,Sam S. Yoon.Noncurative Gastrectomy for Gastric Adenocarcinoma Should only be Performed in Highly Selected Patients[J].Annals of Surgical Oncology.2013(11)
  • 6J. Chen,Z. Tang,X. Dong,S. Gao,H. Fang,D. Wu,D. Xiang,S. Zhang.Radiofrequency ablation for liver metastasis from gastric cancer[J].European Journal of Surgical Oncology.2013(7)
  • 7J.A. Ajani,M. Buyse,M. Lichinitser,V. Gorbunova,G. Bodoky,J.Y. Douillard,S. Cascinu,V. Heinemann,R. Zaucha,A. Carrato,D. Ferry,V. Moiseyenko.Combination of cisplatin/S-1 in the treatment of patients with advanced gastric or gastroesophageal adenocarcinoma: Results of noninferiority and safety analyses compared with cisplatin/5-fluorouracil in the First-Line Advanced Gastric Cancer Study[J].European Journal of Cancer.2013
  • 8Florian Lordick,Yoon-Koo Kang,Hyun-Cheol Chung,Pamela Salman,Sang Cheul Oh,Gy?rgy Bodoky,Galina Kurteva,Constantin Volovat,Vladimir M Moiseyenko,Vera Gorbunova,Joon Oh Park,Akira Sawaki,Ilhan Celik,Heiko G?tte,Helena Melezínková,Markus Moehler.Capecitabine and cisplatin with or without cetuximab for patients with previously untreated advanced gastric cancer (EXPAND): a randomised, open-label phase 3 trial[J].Lancet Oncology.2013(6)
  • 9Lei Jiang,Ke‐Hu Yang,Quan‐Lin Guan,Peng Zhao,Yan Chen,Jin‐Hui Tian.Survival and recurrence free benefits with different lymphadenectomy for resectable gastric cancer: A meta‐analysis[J].J Surg Oncol.2013(8)
  • 10Atsushi Nashimoto,Kohei Akazawa,Yoh Isobe,Isao Miyashiro,Hitoshi Katai,Yasuhiro Kodera,Shunichi Tsujitani,Yasuyuki Seto,Hiroshi Furukawa,Ichiro Oda,Hiroyuki Ono,Satoshi Tanabe,Michio Kaminishi.Gastric cancer treated in 2002 in Japan: 2009 annual report of the JGCA nationwide registry[J].Gastric Cancer.2013(1)

共引文献120

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部